Muscle loss and GLP-1R agonists use
Authors:
Open Access
- 7 November 2025
- journal article
- review article
- Published by Springer Nature in Acta Diabetologica
- Vol. 63 (2) , 333-342
Abstract
Skeletal muscle wasting is a major yet often overlooked determinant of adverse outcomes in diabetes mellitus and obesity. Loss of muscle mass and strength not only impairs mobility and quality of life, but also worsens insulin resistance, accelerates cardiometabolic decline and increases mortality risk. The convergence of chronic inflammation, mitochondrial dysfunction and altered protein metabolism makes individuals with metabolic diseases particularly vulnerable to sarcopenia. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the therapeutic landscape of type 2 diabetes (T2D) and obesity by offering substantial weight loss and cardiometabolic protection. However, clinical trials and real-world evidence consistently show that weight reduction with GLP-1RAs is accompanied by decrease in lean body mass, raising concern in patients already predisposed to muscle wasting and underscoring the need for integrated management strategies. By including all English-language studies on muscle mass loss during GLP-1RA therapy in T2D and obesity from major scientific databases and clinical trial registries, this narrative review synthesizes the current knowledge on the epidemiology and mechanisms of muscle loss in diabetes and obesity, with a focus on the impact of GLP-1RAs therapy. It further examines preventive and therapeutic strategies to preserve muscle health during pharmacological weight loss, with the ultimate aim of providing clinicians and researchers with practical insights and future directions to maximize the benefits of GLP-1RAs while mitigating the risk of sarcopenia.Keywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca (20229ZA2YF)
This publication has 72 references indexed in Scilit:
- Sarcopenia and Sarcopenic Obesity and Mortality Among Older PeopleJAMA Network Open, 2024
- AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitusActa Diabetologica, 2023
- GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy VolunteersDiabetes Therapy, 2023
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2022
- Effect of curcumin supplementation on exercise-induced muscle damage: a narrative reviewEuropean Journal of Nutrition, 2022
- Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and ObesityJAMA Network Open, 2021
- Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older AdultsJAMA Network Open, 2020
- Protein, amino acids and obesity treatmentReviews in Endocrine and Metabolic Disorders, 2020
- Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trialDiabetologia, 2020
- The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trialJournal of Cachexia, Sarcopenia and Muscle, 2011